United States · Wires & real time · PR Newswire

Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis

Published by PR Newswire · United States 1 h ago

HANGZHOU, China, SHANGHAI and BOSTON, Oct. 27, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company…

Read the full article on PR Newswire Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.prnewswire.com)

Also worth reading

Business Wire

Peoples Security Bank & Trust Welcomes Scott Campagna as Executive Vice President, Chief Information Officer

Associated Press (Business)

Baby orangutans in India expose illegal wildlife trade as experts question a billionaire’s zoo

Dow Jones Newswires

Dragonfly On-demand Webinar: Middle East: Anticipating a convergence of conflicts

MT Newswires

Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis

Share

Also worth reading

Peoples Security Bank & Trust Welcomes Scott Campagna as Executive Vice President, Chief Information Officer

Baby orangutans in India expose illegal wildlife trade as experts question a billionaire’s zoo

Dragonfly On-demand Webinar: Middle East: Anticipating a convergence of conflicts

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows